Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Bayer Gets Kythera’s Chin Fat Drug

by Lisa M. Jarvis
September 6, 2010 | A version of this story appeared in Volume 88, Issue 36

Intendis, the dermatology unit of Bayer HealthCare, will pay $43 million upfront for access to Kythera Biopharmaceuticals’ ATX-101, in late-stage trials to reduce small amounts of fat from under the chin. The Los Angeles-based biotech firm could score another $330 million in milestones, in addition to double-digit royalties on sales once the drug reaches the market. The active component of ATX-101 appears to be deoxycholate, a secondary bile acid that does not seem to affect nonfat tissues.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.